Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.62 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inosine SCHEMBL15804 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL18653532 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL20138477 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL298755 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL4110068 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL2046912 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL6748954 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL12763613 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL330178 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL2229394 | 0.88 | SLC29A1 (0.75) | ADORA1DOT1LDPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | claimed |
| EP-3463384-A1 | CANCER TREATMENTS | NuCana plc (GB) | 2019-04-10 | — | — | EP | claimed |
| WO-2017207993-A1 | CANCER TREATMENTS | NUCANA BIOMED LIMITED (GB) | 2017-12-07 | — | — | WO | claimed |
| US-9179994-B2 | Implantable film/mesh composite | COVIDIEN LP (US) | 2015-11-10 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-9005308-B2 | Implantable film/mesh composite for passage of tissue therebetween | COVIDIEN LP (US) | 2015-04-14 | — | — | US | claimed |
| US-8932621-B2 | Implantable film/mesh composite | COVIDIEN LP (US) | 2015-01-13 | — | — | US | claimed |
| US-20140142520-A1 | IMPLANTABLE DEVICES INCLUDING A MESH AND A PIVOTABLE FILM | COVIDIEN LP (US) | 2014-05-22 | — | — | US | claimed |
| EP-2586400-B1 | Implantable film/Mesh composite | COVIDIEN LP (US) | 2014-03-19 | — | — | EP | claimed |
| EP-2586401-B1 | Implantable film/mesh composite | COVIDIEN LP (US) | 2014-03-19 | — | — | EP | claimed |
| US-20020010210-A1 | PHARMACEUTICAL PREPARATION AND METHOD FOR TREATING CANCER | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2002-01-24 | — | — | US | claimed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0875246-A1 | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1998-11-04 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0608546-A2 | Glia activating factor (GAF), antibodies against it and their uses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |
| EP-0476711-A2 | Use of 5-fluorouracil for the treatment of AIDS | Nakai, Masuyo (JP) | 1992-03-25 | — | — | EP | claimed |
| EP-0302263-A2 | Therapeutic composition for combatting AIDS | Nakai, Masuyo (JP) | 1989-02-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010210-A1 | PHARMACEUTICAL PREPARATION AND METHOD FOR TREATING CANCER | PROC, CYP27B1, SLC46A1 | ADORA1 1065/4885DOT1L 4679/4885DPP4 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.